

Backgrounder

More than 34,000 young people reached

More than 18,000 healthcare professionals trained
in the diagnosis and management of type 1 diabetes

More than 240 clinics established or refurbished

More than 160,000 patient education sessions



Hnin Eain, Myanmar
Hnin has type 1 diabetes
and receives treatment and
care through Changing
Diabetes® in Children

About us

Changing Diabetes® in Children is a public-private partnership established in 2009. The partnership provides comprehensive care for children and young people living with type 1 diabetes in low- and middle-income countries. This includes free life-saving medicine and supplies for persons up to 25 years of age.

Learn more at novonordisk.com/cdic

The challenge of type 1 diabetes in low- and middle-income countries

Type 1 diabetes is a lifelong, autoimmune condition that results in impaired insulin production. If left untreated, glucose remains in the bloodstream and causes damage to organs. This can result in severe health complications and, ultimately, in premature death¹.

It is estimated that more than 1.2 million young people under the age of 20 have type 1 diabetes and that approximately 184,100 new cases are diagnosed each year¹.

Although type 1 diabetes is one of the most common chronic childhood illnesses², it is often misdiagnosed in low-resource settings³. Healthcare professionals who are unfamiliar with type 1 diabetes may mistake its symptoms for malaria or another disease that presents in a similar manner⁴.

Insulin, administered by multiple, daily injections, is the only effective long-term treatment for type 1 diabetes⁴. People living in low-resource settings are less likely to have adequate access to healthcare services, including diagnosis, comprehensive care and life-saving insulin.

Consequently, the Changing Diabetes® in Children partnership was established to bridge critical gaps in access to care for these vulnerable children around the world.

The ambition is clear:

no child should die from diabetes.

A complex disease requiring careful management and lifelong care

Treating type 1 diabetes is not simply a matter of access to insulin; it is a complex disease that requires careful management and continuous care⁵. Changing Diabetes® in Children is structured around four components aimed at building a holistic system of care:



Providing comprehensive patient education



Strengthening healthcare professional capacity to diagnose and treat



Bringing care closer to the people who need it



Ensuring access to insulin and other essential supplies, like blood glucose testing kits

A partnership approach to support local healthcare systems

Changing Diabetes® in Children is led by global partners Novo Nordisk, Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In addition, the partnership is dependent on the continued collaboration of local entities, especially ministries of health and implementing partners, including local diabetes associations.

Changing Diabetes® in Children takes a sustainable approach by building on existing efforts to address local barriers to healthcare, supporting the development of comprehensive diabetes care solutions and integrating with local healthcare systems.

A decade of building sustainable solutions

2009

Changing Diabetes® in Children is established, with a strong ambition to improve the capacity of healthcare systems and reach 10,000 children with type 1 diabetes in low- and middle-income countries within five years.

2014

Within the first five years, Changing Diabetes® in Children exceeds this goal by reaching 13,199 children across nine countries.

2019

Novo Nordisk launches its Defeat Diabetes social responsibility strategy and commits to bold new ambitions for Changing Diabetes® in Children.

2022

The partnership reaches more than 34,000 children, has trained more than 18,000 healthcare professionals and has established more than 240 clinics.

2030

The partnership aims to reach 100,000 children and young people living with type 1 diabetes by 2030.

Commitment: Reaching more children and young people by 2030

At the launch of Novo Nordisk's Defeat Diabetes social responsibility strategy in 2019, Changing Diabetes® in Children set an ambitious new goal to reach 100,000 vulnerable children and young people living with type 1 diabetes with diabetes care by 2030.

To achieve this, the partnership has enlarged its footprint, launching in six new countries in 2022, bringing the total to 24. This includes a partnership with the WDF to **integrate type 1 diabetes care into the healthcare systems of eight African and Middle Eastern countries.**



The age limit for Changing Diabetes® in Children eligibility has also been raised from 18 to 25 in 2021, to provide access to a wider population of vulnerable young people.

Partnership countries as of June 2022:

Africa: Cameroon, Côte d'Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Kenya, Malawi, Mozambique, Nigeria, Rwanda, Senegal, Sudan, Tanzania, Uganda. **Middle East:** Jordan, Lebanon. **Asia:** Bangladesh, Cambodia, India, Indonesia, Myanmar, Pakistan. **South America:** Peru
For more information about where the partnership works, visit novonordisk.com/cdic

The global partners

Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and preventing and ultimately curing disease. Novo Nordisk employs about 50,000 people in 80 offices around the world, and markets its products in around 170 countries.

novonordisk.com

Roche Diabetes Care

Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. Today, more than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from their therapy routines. Being a global leader in integrated Personalised Diabetes Management (iPDM) with a comprehensive offering including glucose monitoring, insulin delivery systems and digital solutions Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital platforms as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments.

rochediabetes.com

International Society for Pediatric and Adolescent Diabetes

The International Society for Pediatric and Adolescent Diabetes (ISPAD) is a professional organisation whose aims are to promote clinical and basic science, research, education and advocacy in childhood and adolescent diabetes. The strength of ISPAD lies in the scientific and clinical expertise in childhood and adolescent diabetes of its members. ISPAD is the only international society focusing specifically on all types of childhood diabetes.

ispad.org

World Diabetes Foundation

The World Diabetes Foundation (WDF) is an independent, non-profit foundation based in Bagsværd, Denmark. Founded by Novo Nordisk A/S in 2002, the WDF is still one of the few funding mechanisms dedicated to preventing and treating diabetes in developing countries. It is the WDF's mission to empower governments, civil society and other non-state actors that strive to deliver on global commitments through national and local action.

worlddiabetesfoundation.org



1. International Diabetes Federation. *IDF Diabetes Atlas, 10 ed.* Brussels, Belgium: International Diabetes Federation;2021. 2. Streisand R, Monaghan M. Young children with type 1 diabetes: challenges, research, and future directions. *Current diabetes reports.* 2014;14(9):520. 3. Beran D, Yudkin JS, De Courten M. Access to care for patients with insulin-requiring diabetes in developing countries: case studies of Mozambique and Zambia. *Diabetes care.* 2005;28(9):2136–2140. 4. Yarhere IE, Tamunopriye J. Survey on knowledge of healthcare providers about childhood Diabetes Mellitus in tertiary healthcare institution in a resource-limited setting. *Nigerian Health Journal.* 2016;16(3). 5. WHO. *Global report on diabetes.* World Health Organization;2016.